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presence of EGFR mutations (odds ratio, 0.019; 95% CI, 0.001-0.298; 
P=0.005) was signiﬁcantly associated with the higher response rate to 
geﬁtinib. Progression-free survival (6.6 vs. 3.3 months; p=0.246) and 
overall survival (8.1 vs. 8.6 months; p=0.397) were similar between 
patients with EGFR mutations and those with wild-type EGFR.
Conclusion: Clinical response to geﬁtinib in this study was linked to 
the presence of EGFR mutations. Given the limitation of small sample 
size, EGFR mutations were not associated with the speciﬁc clinical 
predictors for geﬁtinib responsiveness.
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Background: Retrospective analyses of previous trials have shown the 
clinical advantage of geﬁtinib in advanced non-small cell lung cancer 
(NSCLC) patients with certain favorable baseline factors (Asian ethnic-
ity, female, adenocarcinoma, or no smoking history). This prospective 
phase II study was designed to test the hypothesis that higher response 
rates might be achieved if patients are selected according to these clini-
cal predictors for response.
Methods: Korean NSCLC patients who have failed after docetaxel-
based ﬁrst-line chemotherapy were consecutively accrued. Patients 
without any of the favorable clinical predictors (i.e., male smoker with 
non-adenocarcinoma) received irinotecan 100 mg/m2 on days 1, 8 and 
15 every 4 weeks (irinotecan arm). Patients who had at least one of the 
predictors for response received geﬁtinib 250 mg/d orally from day 1 
(geﬁtinib arm). Primary endpoint was response rate. With a two-stage 
phase II design, the required number of patients was at least 25 per 
each arm.
Results: Of 68 patients accrued, 25 were treated with irinotecan and 
43 with geﬁtinib. In the geﬁtinib arm, 22 patients were female, 20 were 
never-smoker, and 33 had adenocarcinoma. Treatment duration was 
signiﬁcantly longer in the geﬁtinib arm (2.0 months for irinotecan arm 
v 3.9 months for geﬁtinib arm; p<0.01). Median number of chemother-
apy cycles was 2 (range, 1-6) for irinotecan arm. Fewer drug-related 
toxicities were observed with geﬁtinib compared with irinotecan. In 
the irinotecan and geﬁtinib arm, 36% and 9% of patients, respectively, 
discontinued treatment because of toxicity. The objective responses of 
irinotecan and geﬁtinib arm were 16% (95% CI, 2-30) and 40% (95% 
CI, 25-54), respectively (p=0.04). Patients in the geﬁtinib arm had a 
longer (p=0.04), progression-free survival (5.3 months; 95% CI, 1.7-
8.8) than those in the irinotecan arm (3.2 months; 95% CI, 1.7-4.6).
Conclusion: Geﬁtinib could be a reasonable second-line option in Ko-
rean NSCLC patients who had at least one favorable clinical predictor.
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Background: Erlotinib is an orally active and selective inhibitor of 
HER1/EGFR tyrosine kinase, which gained approval for the treat-
ment of previously treated patients with advanced non-small cell lung 
cancer (NSCLC). The randomized, phase III study BR.21 demonstrated 
a signiﬁcant survival beneﬁt for patients with advanced NSCLC who 
received erlotinib versus placebo (HR: 0.70, 95% CI 0.58–0.85), after 
failure to one or more previous treatments. The TargeT trial is a large, 
Spanish, non-randomized, phase II trial evaluating the efﬁcacy and 
safety of erlotinib in patients with advanced or metastatic NSCLC.
Methods: Patients with previously treated advanced or metastatic 
NSCLC or patients that were not suitable for ﬁrst line conventional 
chemotherapy, stage IIIB/IV, PS 0-2 were enrolled to receive oral erlo-
tinib 150 mg/day until disease progression or withdrawal. The primary 
endpoint of the study was time to progression (TTP) in the intent to 
treat (ITT) population. 
Results: 1,796 patients were enrolled from June 04 to March 06 and 
1,539 evaluated for this analysis. Demographics: median age 65 y 
[range 26–95]; male: 72%; stage IV: 82%; PS 0/1/2: 21%/54%/25%; 
adenocarcinoma histology: 53%, SCC: 25.0%, LCC: 16%, other: 6%; 
current/former smoker: 78%. Patients receiving erlotinib as 1st/2nd/
≥3rd line were 29%/39%/33%, respectively. 879 were analyzed for 
response: 11 patients reached CR (1%), 154 PR (18%), for and overall 
response rate of 19%. Control disease rate was 58%.
In the exploratory subgroup analysis, higher response rate (RR) was 
related to female gender (35.9% vs. 11.1%; p<0.0001), the absence 
of smoking habits (42.2% vs. 11.7%; p<0.0001) and adenocarcinoma 
histology (25.8 vs. 11.4; p<0.0001). Patients receiving erlotinib in the 
ﬁrst line setting reached signiﬁcantly higher RRs (31.5%) than in fur-
ther lines of treatment (13.8%; p<0.0001). All these factors remained 
as predictive factors for response in the multivariate analysis, with 
the exception of gender. Similar results were found regarding control 
disease rate. 
In the ITT population, median time to progression was 3.9 months 
[95% CI 3.5–4.4] and median overall survival 6.1 months [95% CI 
5.5–6.4 months]. Statistically signiﬁcant differences were found in 
favor of nonsmokers (TTP and OS: p<0.0001), patients with a good 
performance status (TTP: p=0.004; OS: p<0.0001) and adenocarcinoma 
(for the comparison with other grouped histologies; TTP: p=0.002; 
OS: p<0.0001), both in the univariate and multivariate analysis (p 
refers to the latter analysis). Interestingly, no differences between 
adenocarcinoma and SCC speciﬁcally were detected. Treatment in the 
ﬁrst line setting was also associated with longer TTP in the Cox model 
(P=0.002), but not with longer survival. Finally, female gender did not 
signiﬁcantly associate with TTP or survival.
